CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Old API Wind-Down Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Old API Wind-Down Ltd
666 Burrard Street
Phone: (905) 876-1118p:905 876-1118 Vancouver, BC  V6C 2X8  Canada Fax: (905) 567-4618f:905 567-4618
This company is no longer actively traded on any major stock exchange.
Business Summary
Old API Wind-Down Ltd, formerly known as Aralez Pharmaceuticals Inc., is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company's products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G. Its development products include YOSPRALA and Bilastine. Fibricor (fenofibric acid) is indicated as a complementary therapy along with diet for the treatment of hypertriglyceridemia, and as a complementary therapy along with diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG) and apolipoprotein B (Apo B). Fibricor is also used to increase high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with hypercholesterolemia or mixed dyslipidemia. Cambia (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug (NSAID).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/201812/31/2017YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Arthur S.Kirsch 63 2/5/2016 2/5/2016
President, Chief Business Officer Andrew I.Koven 60 2/5/2016 2/5/2016
Chief Executive Officer, Director AdrianAdams 67 2/5/2016 2/5/2016
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Aralez Pharmaceuticals Holdings Limited 2 Hume Street Dublin Ireland
Aralez Pharmaceuticals Trading Designated Activity Company 2 Hume Street Dublin Ireland
Aralez Pharmaceuticals US Inc. 400 Alexander Park Drive Princeton NJ United States
3 additional Subsidiary records available in full report.

Business Names
Business Name
Aralez Luxembourg Finance
Aralez Luxembourg Finance
Aralez Pharmaceuticals Canada Inc.
21 additional Business Names available in full report.

General Information
Outstanding Shares: 67,194,277 (As of 5/10/2018)
Stock Exchange: OTC
Fax Number: (905) 567-4618


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023